• iOWH’s large-scale clinical trial has proved that paromomycin is a safe and effective cure for VL and has significant advantages over the existing treatments. (Its one disadvantage is that it must be injected; there is one treatment that can be administered orally but is more expensive and cannot be given to women of childbearing age.)
  
  
• With iOWH’s help, an Indian pharmaceutical firm has developed a safe and efficient process to produce paromomycin at a price of about $10 for a full course of treatment, significantly less than any other available treatment.
  
  
• iOWH’s work on paromomycin has proved to us and to others that a nonprofit organization can help correct the “market failure” that results when there are inadequate incentives for private industry to address neglected diseases. Paromomycin would have languished in obscurity if not for iOWH’s efforts.
  
  
• Even prior to formal approval of the drug, the Indian government, with support from the World Bank, is already looking at ways it can incorporate paromomycin into its countrywide disease-control strategies.

Next: Key Lessons